Entellus Medical

The specific founders of Entellus Medical are not widely disclosed in public records beyond general medical device entrepreneur origins. The company was founded by a team of medical device professionals in Maple Grove, Minnesota, but names of individual founders are not publicly available.

Entellus Medical developed the XprESS Multi-Sinus Dilation System, a balloon dilation device designed for minimally invasive treatment of chronic rhinosinusitis. The system allowed surgeons to dilate multiple sinus passageways with a single device, differentiating it from earlier balloon dilation products. It was FDA-cleared and marketed globally.

After Stryker Corporation acquired Entellus Medical in 2016 for about $1.1 billion, the firm became part of Stryker’s Neurotechnology and ENT division. The XprESS system continues to be sold under Stryker’s brand. Entellus Medical no longer operates independently; its operations and team were integrated into Stryker.

Based on available public information, Entellus Medical is not a family office but rather a medical device operating company that was acquired by Stryker Corporation. No secondary structure as a family office or investment vehicle has been disclosed. Its designation in the Altss record appears to be a misclassification.

Entellus Medical was headquartered in Maple Grove, Minnesota, United States. The facility served as the firm’s primary office and likely housed its manufacturing and R&D operations. No additional offices have been publicly documented beyond this single location.

The XprESS Multi-Sinus Dilation System was distinctive because it could dilate multiple sinus passageways — including the frontal, maxillary, and sphenoid sinuses — with a single device insertion. This streamlined procedure time and reduced the need for multiple instruments, giving Entellus Medical a competitive advantage in the balloon sinus dilation market.

Yes, in addition to its primary market in the United States, Entellus Medical expanded into international markets including Europe and Asia. The XprESS system received regulatory clearances in several countries, and the firm built a commercial infrastructure to support global sales. However, the majority of its revenue was likely generated domestically.